MS: Busting the Myths
June 22, 2023 | Advocacy, Funding, Media, Progressive
Multiple Sclerosis New Zealand (MSNZ) is delighted to share that Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to […]
January 26, 2021 | Covid-19, Life with MS, Research, Treatments
This article, written by the Journal of Multiple Sclerosis and related disorders, (MSARD) includes data from clinical trials, post marketing safety surveillance and a US electronic medical records database, Optum. The objective was to better understand the SARS-CoV-2 infection in […]